01—Abstract
Summary
Summary of the 8-K filed May 19, 2025. Cited figures are marked; the original filing is the authoritative source.
On May 16, 2025, Royalty Pharma Holdings Ltd. (RPH), a subsidiary of Royalty Pharma plc, completed the previously announced Transaction under the Membership Interests Purchase Agreement dated January 10, 2025 (as amended April 11, 2025) and acquired all equity interests of Royalty Pharma Manager, LLC (f/k/a Royalty Pharma, LLC) from the Sellers.
The aggregate consideration consisted of $200,000,000a in cash, less certain 2025 management fee payments received by RP Management and RP LLC from January 1 through May 16, 2025, subject to customary adjustments, plus 24,530,266 non-voting Class E ordinary shares of RPH. RPH also assumed RP Management's $380 million term loan facility. In connection with the closing, RP Management was released as a borrower and guarantor under the existing loan agreement and guaranty dated December 11, 2023, while RPH and RP LLC were joined as borrowers and guarantors under the amended loan agreement with Bank of America, N.A.
The filing also reports an amended and restated exchange agreement allowing certain recipients to exchange Class E shares of RPH (after redesignation into Class B shares) for the company's Class A ordinary shares on a one-for-one basis, and amended and restated articles of association for both Royalty Pharma plc and RPH. For management, the filing states that the Named Executive Officers (Pablo Legorreta, Terrance Coyne, Christopher Hite, George Lloyd and Marshall Urist) entered into offer letters providing one year of base salary continuation upon termination without cause or resignation for good reason, subject to a release and continued restrictive covenant compliance. Pablo Legorreta's share consideration vests straight-line over five years, and other RP Management members' shares vest straight-line over ten years beginning in 2024.
02—Key points
Key Highlights
- Transaction closed May 16, 2025: RPH acquired all equity interests of Royalty Pharma Manager, LLC (f/k/a Royalty Pharma, LLC) from the Sellers.
- Cash consideration of $200,000,000, less certain 2025 management fee payments made to and received by RP Management and RP LLC from January 1 through May 16, 2025, subject to customary adjustments.
- Share consideration of 24,530,266 non-voting Class E ordinary shares of RPH, with Sellers subscribing for an equal number of Class B ordinary shares of the company at nominal value.
- RPH assumed RP Management's $380 million term loan facility and all outstanding indebtedness under it.
- RP Management was released as borrower and guarantor under the December 11, 2023 loan agreement; RPH and RP LLC were joined as borrowers and guarantors under the amended loan agreement with Bank of America, N.A.
- Amended and Restated Exchange Agreement allows exchange of redesignated Class E (and other Class B) shares of RPH for Class A ordinary shares of the company on a one-for-one basis.
- Executive Offer Letters for five Named Executive Officers provide one year of base salary continuation upon termination without cause or resignation for good reason, subject to a release and restrictive covenant compliance.
03—Questions
Frequently Asked Questions
What did Royalty Pharma acquire and what did it pay?
RPH acquired all equity interests of Royalty Pharma Manager, LLC (f/k/a Royalty Pharma, LLC) from the Sellers. The consideration was $200,000,000 in cash, less certain 2025 management fee payments received from January 1 through May 16, 2025, subject to customary adjustments, plus 24,530,266 non-voting Class E ordinary shares of RPH. RPH also assumed the $380 million term loan facility of RP Management.
Does the transaction add debt to Royalty Pharma?
The filing states that RPH assumed RP Management's $380 million term loan facility and all outstanding indebtedness under it. It also describes the amended loan agreement under which RPH and RP LLC became borrowers and guarantors alongside the Entity Guarantors and Individual Guarantor.
How can the Sellers' shares be converted into Class A shares?
Under the Amended and Restated Exchange Agreement, recipients can exchange non-voting Class E ordinary shares of RPH, after any redesignation into Class B ordinary shares of RPH, or other Class B ordinary shares they hold, for the company's Class A ordinary shares on a one-for-one basis.
Are there vesting or forfeiture conditions on the share consideration?
Yes. Pablo Legorreta's share consideration vests straight-line over five years and is subject to forfeiture if he resigns or voluntarily ceases his business relationship with the company group during that period, is terminated for cause, or breaches certain restrictive covenants. Other RP Management management members' shares vest straight-line over ten years beginning in 2024 and are subject to forfeiture if their employment terminates for any reason, subject to certain exceptions.
What changed for senior executives?
Effective at closing, Royalty Pharma, LLC entered into Executive Offer Letters with Pablo Legorreta, Terrance Coyne, Christopher Hite, George Lloyd and Marshall Urist. These provide one year of base salary continuation upon termination without cause or resignation for good reason, subject to a release of claims and continued compliance with restrictive covenants.
04—Continue